Assignee
BIOHAVEN THERAPEUTICS LTD
US·19 granted patents·34 pending applications·28 citations·filing 2017–2025
Top patents by PatentIndex Score
53 records- 0197US11052070B2Riluzole prodrugs and their useBIOHAVEN THERAPEUTICS LTD·Filed 2019·Granted Jul 6, 2021·9 cites·3 claims
- 0296US12005047B2Riluzole prodrugs and their useBIOHAVEN THERAPEUTICS LTD·Filed 2023·Granted Jun 11, 2024·2 cites·6 claims
- 0396US10905681B2Riluzole prodrugs and their useBIOHAVEN THERAPEUTICS LTD·Filed 2019·Granted Feb 2, 2021·15 cites·11 claims
- 0494US2026041673A1Prodrugs of riluzole and their method of useBIOHAVEN THERAPEUTICS LTD·Filed 2025·Application pending·0 cites
- 0591US11911369B2Prodrugs of riluzole and their method of useBIOHAVEN THERAPEUTICS LTD·Filed 2020·Granted Feb 27, 2024·2 cites·9 claims
- 0689US12472165B2Riluzole prodrugs and their useBIOHAVEN THERAPEUTICS LTD·Filed 2023·Granted Nov 18, 2025·0 cites·4 claims
- 0788US12351559B2Benzoimidazol benzomidazol-1,2-yl amides as Kv7 channel activatorsBIOHAVEN THERAPEUTICS LTD·Filed 2023·Granted Jul 8, 2025·0 cites·16 claims
- 0886US2025360208A1Use of glutamate modulating agents with immunotherapies to treat cancerBIOHAVEN THERAPEUTICS LTD·Filed 2025·Application pending·0 cites
- 0983US12286408B2KV7 channel activators compositions and methods of useBIOHAVEN THERAPEUTICS LTD·Filed 2023·Granted Apr 29, 2025·0 cites·16 claims
- 1079US12213965B2Riluzole prodrugs and their useBIOHAVEN THERAPEUTICS LTD·Filed 2021·Granted Feb 4, 2025·0 cites·5 claims
- 1178US12005046B2Riluzole prodrugs and their useBIOHAVEN THERAPEUTICS LTD·Filed 2021·Granted Jun 11, 2024·0 cites·8 claims
- 1278US2025114301A1Sublingual formulation of riluzoleBIOHAVEN THERAPEUTICS LTD·Filed 2024·Application pending·0 cites
- 1377US2023310595A1Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancersBIOHAVEN THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 1476US2024358685A1Acyl benzo[d]thiazol-2-amine and their methods of useBIOHAVEN THERAPEUTICS LTD·Filed 2024·Application pending·0 cites
- 1575US11834418B2Benzoimidazol-1,2-yl amides as Kv7 channel activatorsBIOHAVEN THERAPEUTICS LTD·Filed 2020·Granted Dec 5, 2023·0 cites·20 claims
- 1671US2025171429A1Pyrazolyl compounds as kv7 channel activatorsBIOHAVEN THERAPEUTICS LTD·Filed 2023·Application pending·0 cites
- 1768US12295942B2Riluzole prodrugs and their useBIOHAVEN THERAPEUTICS LTD·Filed 2021·Granted May 13, 2025·0 cites·5 claims
- 1868US11083711B2Amine prodrugs of pharmaceutical compoundsBIOHAVEN THERAPEUTICS LTD·Filed 2019·Granted Aug 10, 2021·0 cites·4 claims
- 1968US2025332148A1Riluzole prodrugs and their useBIOHAVEN THERAPEUTICS LTD·Filed 2025·Application pending·0 cites
- 2067US12121609B2Sublingual formulation of riluzoleBIOHAVEN THERAPEUTICS LTD·Filed 2020·Granted Oct 22, 2024·0 cites·14 claims
- 2167US12102618B2Use of riluzole prodrugs to treat ataxiasBIOHAVEN THERAPEUTICS LTD·Filed 2023·Granted Oct 1, 2024·0 cites·13 claims
- 2266US2025230152A1Pyrazolyl compounds as kv7 channel activatorsBIOHAVEN THERAPEUTICS LTD·Filed 2025·Application pending·0 cites
- 2364US2025312316A1Methods of use for kv7 channel activatorsBIOHAVEN THERAPEUTICS LTD·Filed 2025·Application pending·0 cites
- 2463US12383619B2Use of glutamate modulating agents with immunotherapies to treat cancerBIOHAVEN THERAPEUTICS LTD·Filed 2017·Granted Aug 12, 2025·0 cites·24 claims
- 2563US2021236470A1Prodrugs of riluzole and their method of useBIOHAVEN THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 2663US2025171430A1Pyrazolyl compounds as kv7 channel activatorsBIOHAVEN THERAPEUTICS LTD·Filed 2023·Application pending·0 cites
- 2762US2025171405A1Pyrazolyl compounds as kv7 channel activatorsBIOHAVEN THERAPEUTICS LTD·Filed 2023·Application pending·0 cites
- 2861US2026014123A1Use of riluzole oral disintegrating tablets for treating diseasesBIOHAVEN THERAPEUTICS LTD·Filed 2025·Application pending·0 cites
- 2961US2024383961A1Conjugated antibodies for treating diseasesBIOHAVEN THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 3061US2025066351A1Pyrazolo[1,5-a]pyridin-2,3-yl amides as kv7 channel activatorsBIOHAVEN THERAPEUTICS LTD·Filed 2023·Application pending·0 cites
- 3160US2024309114A1Bifunctional degraders of galactose-deficient immunoglobulinsBIOHAVEN THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 3260US2024252674A1Agents for directed conjugation techniques and conjugated productsBIOHAVEN THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 3359US2025108124A1Antibody drug conjugates using mates technology for delivering cytotoxic agentsBIOHAVEN THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 3458US2024238436A1Compositions including conjugated therapy enhancersBIOHAVEN THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 3557US12564579B2Topical formulations of (1S)-1-phenyl-2-pyridin-2-ylethanamineBIOHAVEN THERAPEUTICS LTD·Filed 2021·Granted Mar 3, 2026·0 cites·15 claims
- 3657US12370176B2Methods of use for KV7 channel activatorsBIOHAVEN THERAPEUTICS LTD·Filed 2020·Granted Jul 29, 2025·0 cites·11 claims
- 3757US2024082340A1Use of riluzole prodrugs to treat alzheimer's diseaseBIOHAVEN THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 3857US2024148722A1Small molecules that bind to tdp-43 for the treatment of als and related disordersBIOHAVEN THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 3956US12201618B2Use of riluzole prodrugs to treat Alzheimer's diseaseBIOHAVEN THERAPEUTICS LTD·Filed 2021·Granted Jan 21, 2025·0 cites·7 claims
- 4054US12161633B2Use of riluzole prodrugs to treat alzheimer's diseaseBIOHAVEN THERAPEUTICS LTD·Filed 2019·Granted Dec 10, 2024·0 cites·13 claims
- 4153US2023181541A1Compositions and methods for treating obsessive-compulsive disorderBIOHAVEN THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 4253US2021315865A1Use of riluzole oral disintigrating tablets for treating diseasesBIOHAVEN THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 4353US2023330240A1Technologies for preventing or treating infectionsBIOHAVEN THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 4450US2022388962A1Molecules that bind to tdp-43 for the treatment of amyotrophic lateral sclerosis and related disordersBIOHAVEN THERAPEUTICS LTD·Filed 2020·Application pending·0 cites
- 4550US2024067651A1Prodrugs of myeloperoxidase inhibitorsBIOHAVEN THERAPEUTICS LTD·Filed 2020·Application pending·0 cites
- 4650US2026034231A1Bifunctional degraders for the treatment of graves diseaseBIOHAVEN THERAPEUTICS LTD·Filed 2025·Application pending·0 cites
- 4750US2025375427A1Methods of treating glioblastoma with prodrugs of riluzoleBIOHAVEN THERAPEUTICS LTD·Filed 2023·Application pending·0 cites
- 4849US2024335555A1Technologies for preventing or treating infectionsBIOHAVEN THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 4949US2026091024A1Prodrugs of riluzole and their method of useBIOHAVEN THERAPEUTICS LTD·Filed 2025·Application pending·0 cites
- 5048US2025228957A1Bifunctional degraders of galactose-deficient immunoglobulinsBIOHAVEN THERAPEUTICS LTD·Filed 2025·Application pending·0 cites
Showing the top 50 of 53 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when BIOHAVEN THERAPEUTICS LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →